Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report

 Products Recall, Stock Price Updates, Technology Solution Deployment, Update
    on Extension Trial, and Donations - Research Report on Alexion Pharma,
               Questcor, BioMarin Pharma, Allscripts, and Prana

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 20, 2013

NEW YORK, December 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), Questcor Pharmaceuticals, Inc. (NASDAQ:
QCOR), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Allscripts Healthcare
Solutions, Inc. (NASDAQ: MDRX), and Prana Biotechnology Ltd. (NASDAQ: PRAN).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report 

On December 13, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced
additional information regarding a previously communicated voluntary recall of
two lots of Soliris (eculizumab) Concentrated Solution for Intravenous
Infusion. According to the Company, on November 12, 2013, Soliris®
(eculizumab), 300 mg/30 mL, lot 10010A, and Concentrated Solution for
Intravenous Infusion, NDC 25682-001-01, lot 10001-1, were found to contain
visible particles, and hence Alexion provided instructions to return any
unused vials of Soliris from these two lots at the distributor level at that
time. The Company stated that it has now provided the same instructions at the
hospital/user level, directing any person in possession of vials of Soliris
from the above mentioned lots to stop its usage and arrange to return the same
to Alexion immediately by calling 1-888-SOLIRIS (888-765-4747). The Company
informed that it will replace any recalled vials of Soliris and till the date
of announcement, visible particles have not been observed in other lots of
Soliris distributed in the US. Alexion added that adverse reactions or quality
problems experienced with the use of this product may be reported to the FDA's
MedWatch Adverse Event Reporting program either online, by regular mail or by
fax. The Full Research Report on Alexion Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/4619_ALXN

Questcor Pharmaceuticals, Inc. Research Report

On December 17, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that
it has made a $25,000 donation to the Children's Hospital & Research Center
Oakland in support of the Early Intervention Services program. According to
the Company, the Early Intervention Services program supports the well-being,
development and caregiving relationships of infants and young children (up to
age 6) who have developmental, social-emotional and medically related
vulnerabilities or disabilities. Steve Cartt, Chief Operating Officer for
Questcor, said, "We feel privileged to be able to support such a worthy
institution, particularly one that is funded solely by grants and charitable
contributions. Our hope is that these funds will help improve the quality of
life for some Bay Area children who are in need." The Full Research Report on
Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a415_QCOR

BioMarin Pharmaceutical Inc. Research Report

On December 17, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin Pharmaceutical)
stock declined 1.62%, ending the day's session at $68.09. Over the previous
three trading sessions, shares of BioMarin Pharmaceutical declined 0.19%,
compared to the Nasdaq Composite which increased 0.63% during the same period.
The Full Research Report on BioMarin Pharmaceutical Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

Allscripts Healthcare Solutions, Inc. Research Report

On December 12, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts)
reported that Springhill Medical Center, a private, full service hospital
located in Mobile, Alabama, has selected Allscripts Sunrise Surgical Care to
help improve operational efficiency, leveraging their existing Allscripts
Sunrise investment to deliver a higher quality of care and better
perioperative experience for its patients, surgeons and clinicians. Mark
Kilbo, Chief Information Officer at Springhill Medical Center, said,
"Springhill chose Sunrise Surgical Care because there is tremendous technical
benefit to having surgical and clinical solutions on the same platform. A
single platform assures the quality and integrity of data, improves clinical
and financial outcomes and with only one platform to support, ensures a lower
total long-term cost of ownership." The Full Research Report on Allscripts
Healthcare Solutions, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1787_MDRX

Prana Biotechnology Ltd. Research Report

On December 11, 2013, Prana Biotechnology Ltd. (Prana) provided an update of
its IMAGINE Alzheimer's Disease (AD) Extension trial. According to the
Company, in July 2013, the Austin Health Human Research Ethics Committee
(HREC) approved a 12-month open label extension study for patients completing
the double- blind placebo-controlled IMAGINE trial. Prana informed that the
approval was followed by a full review by the Austin Health HREC of the
potential benefit to patients and safety data collected during the IMAGINE
trial, and the Company provided all patients in the IMAGINE trial the
opportunity to participate in the Extension trial. According to Prana, a total
of 33 patients chose to go into the Extension trial, representing 83% of the
40 patients who completed 12 months of treatment in the IMAGINE trial. The
Company added that the independent Data Safety Monitoring Board recently met
to review the available safety data from the Extension trial, and has
recommended that the study proceed without change to the original protocol.
The Full Research Report on Prana Biotechnology Ltd. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/9f3a_PRAN

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.